Drug intelligence / Profile preview

Shabairunfei

Development stage: Preclinical
Administration: Oral (presumed Based On Standard Tcm Practice)

Overview

Shabairunfei is a traditional Chinese medicine (TCM) formula evaluated for its potential to prevent acute radiation pneumonia. It is not a single chemical entity but rather a multi-herb formulation, typical of TCM approaches, and is being studied for its clinical efficacy in reducing the incidence or severity of radiation-induced lung injury. The precise mechanism of action has not been fully elucidated, but such formulas often exert anti-inflammatory and immunomodulatory effects. The primary indication under investigation is the prevention of acute radiation pneumonia in patients undergoing radiotherapy[2].

Brand names: Shabairunfei
Other names: Shabairunfei formula

Beyond the preview

Go deeper on Shabairunfei.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shabairunfei.

Explore the full profile